These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27423371)

  • 1. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
    Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
    Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular inflation, attrition and the rule of five.
    Leeson PD
    Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
    Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
    Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
    J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity.
    Hill AP; Young RJ
    Drug Discov Today; 2010 Aug; 15(15-16):648-55. PubMed ID: 20570751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity.
    Young RJ; Green DV; Luscombe CN; Hill AP
    Drug Discov Today; 2011 Sep; 16(17-18):822-30. PubMed ID: 21704184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic physical properties and structural fragments of marketed oral drugs.
    Vieth M; Siegel MG; Higgs RE; Watson IA; Robertson DH; Savin KA; Durst GL; Hipskind PA
    J Med Chem; 2004 Jan; 47(1):224-32. PubMed ID: 14695836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there enough focus on lipophilicity in drug discovery?
    Lobo S
    Expert Opin Drug Discov; 2020 Mar; 15(3):261-263. PubMed ID: 31736369
    [No Abstract]   [Full Text] [Related]  

  • 13. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new paradigm for navigating compound property related drug attrition.
    Barton P; Riley RJ
    Drug Discov Today; 2016 Jan; 21(1):72-81. PubMed ID: 26404453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-related differences in the physical property profiles of oral drugs.
    Leeson PD; Davis AM
    J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of acid/base properties in drug discovery.
    Manallack DT; Prankerd RJ; Yuriev E; Oprea TI; Chalmers DK
    Chem Soc Rev; 2013 Jan; 42(2):485-96. PubMed ID: 23099561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the 'organizational factor' on compound quality in drug discovery.
    Leeson PD; St-Gallay SA
    Nat Rev Drug Discov; 2011 Sep; 10(10):749-65. PubMed ID: 21959288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution.
    Henchoz Y; Bard B; Guillarme D; Carrupt PA; Veuthey JL; Martel S
    Anal Bioanal Chem; 2009 Jun; 394(3):707-29. PubMed ID: 19184676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in aqueous solubility achieved via small molecular changes.
    Walker MA
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5100-5108. PubMed ID: 29100802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.